WHO ICTRP trial
Clinical study of autologous mouse-derived BCMA-CART in the treatment of…
ChiCTR1900024388 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1900024388 |
|---|---|
| Public title | Clinical study of autologous mouse-derived BCMA-CART in the treatment of relapsed and refractory multiple myeloma |
| Scientific title | Clinical study of autologous mouse-derived BCMA-CART in the treatment of relapsed and refractory multiple myeloma |
| Primary sponsor | Beijing Boren Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | Relapsed and refractory multiple myeloma |
| Interventions | treatment group:Murine BCMA-CART Cell Immunotherapy |
| Registration date | Jul 9, 2019 |
| Target size | treatment group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: